Journal article
Human antigen-specific CD4 CD25 CD134 CD39 T cells are enriched for regulatory T cells and comprise a substantial proportion of recall responses
N Seddiki, L Cook, DC Hsu, C Phetsouphanh, K Brown, Y Xu, SJ Kerr, DA Cooper, CML Munier, S Pett, J Ananworanich, J Zaunders, AD Kelleher
European Journal of Immunology | WILEY | Published : 2014
Abstract
Human Ag-specific CD4+ T cells can be detected by their dual expression of CD134 (OX40) and CD25 after a 44 hours stimulation with cognate Ag. We show that surface expression of CD39 on Ag-specific cells consistently identifies a substantial population of CD4+CD25+CD134+CD39+ T cells that have a Treg-cell-like phenotype and mostly originate from bulk memory CD4+CD45RO+CD127lowCD25highCD39+ Treg cells. Viable, Ag-specific CD25+CD134+CD39+ T cells could be expanded in vitro as cell lines and clones, and retained high Forkhead Box Protein 3, CTLA-4 and CD39 expression, suppressive activity and Ag specificity. We also utilised this combination of cell surface markers to measure HIV-Gag responses..
View full abstractRelated Projects (1)
Grants
Awarded by NHMRC
Funding Acknowledgements
The authors would like to thank all the patients and donors for their cooperation in providing blood samples, Michelle Bailey for assistance in flow cytometric isolation of T-cell populations and Karen MacRae for assistance in patient recruitment. We also thank Dr. David Van Bockel for his assistance with manuscript editing. This study was funded from the following sources: the Australian Government Department of Health and Ageing; the NHMRC via a Program (510448) grant, a Practitioner Fellowship (A. D. K.), an NHMRC postgraduate scholarship (D. C. H. and Y.X.) and an Australian postgraduate award and University of New South Wales research excellence scholarship (L. C.). The views expressed in this publication do not necessarily represent the position of the Australian Government. The Kirby Institute is affiliated with the Faculty of Medicine, University of New South Wales, Sydney, Australia. N.S., J.Z. and A. K., in conjunction with St Vincent's Hospital, Sydney, Australia, hold a patent application for the CD25<SUP>+</SUP>CD134<SUP>+</SUP>CD39<SUP>+</SUP> assay (PCT/AU2008/001407, 2008).